Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Organon & Co. Common Stock — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73 (market cap $382.97M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 9.5× JPMorgan Diversified Return International Eqty ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while JPMorgan Diversified Return International Eqty ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 121 Days and Organon & Co. Common Stock for 0 Days on average.
| JPIN | OGN | |
|---|---|---|
Market Cap | $382.97M | $3.62B |
Volume | 1,797 | 2,892,999 |
52-Week High | $77.80 | $13.81 |
52-Week Low | $65.86 | $5.70 |
Typical Hold Time | 121 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN, the JPMorgan Diversified Return International Equity ETF, trades at $73.52, up 0.65% today. Technical indicators are overwhelmingly bearish, with moving averages and oscillators signaling selling pressure, though the RSI suggests potential oversold conditions. The ETF provides broad exposure to international large-cap value stocks. A dividend of $0.51 is scheduled for payment in September 2026.
The outlook is cautious due to strong bearish technical signals. The primary opportunity lies in the ETF's international diversification and value focus, but risks include global market volatility and the current negative momentum. Investors should weigh the oversold RSI against the dominant sell signals.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
